Ginkgo Bioworks Holdings, Inc. (DNA) shares rallied 18.9% in the last trading session to close at $11.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the potential of Ginkgo’s proprietary cell programming platforms, Foundry and Codebase. The company offers R&D services ut ...

Core Insights - Ginkgo Bioworks has made significant progress in its restructuring efforts, targeting $250 million in cost savings by Q3 2025 [1][3][7] - The company reported a total revenue of $48 million for Q1 2025, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release [6][22] - Ginkgo's Solutions business is becoming a trusted R&D service provider for the US Government and biopharma industry, while its Tools business is gaining traction in AI-related opportunities [3][7] Financial Performance - Q1 2025 total revenue was $48 million, with $31 million from Cell Engineering (up 10% year-over-year) and $10 million from Biosecurity (flat year-over-year) [6][22] - The company reported a GAAP net loss of $91 million for Q1 2025, an improvement from a net loss of $166 million in the prior year [6][22] - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, driven by increased revenue and reduced operating expenses [6][22] Strategic Positioning - Ginkgo is well-positioned in the biotechnology sector, with 28 US Government projects and a contracted backlog of approximately $180 million [7] - The company is focusing on biosecurity and R&D services, which are deemed critical by national policy reports [7] - Ginkgo's Datapoints and Automation offerings are generating new deals, including a recent agreement with Aura Genetics [7] Guidance and Outlook - Ginkgo has updated its 2025 guidance to reflect total revenue expectations of $160-$180 million, with Cell Engineering revenue projected at $110-$130 million and Biosecurity revenue at least $50 million [5][13] - The company aims to achieve Adjusted EBITDA breakeven by the end of 2026 [7]

Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors. The achievement grants Ginkgo with additional equity in Phytolon, and paves the way to explore further collaborations in the field of natural food colors.YOKNE'AM ILLIT, Israel and BOSTON, April 30 ...

Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Gink ...